Spatial multi‐omics unveils sphingolipid metabolic reprogramming within the retinal pathological niche
It is revealed that spatially defined immunometabolic remodeling—in which Trem2 + microglia are central—converges on sphingolipid metabolism as a druggable regulatory axis, with the TREM2‐SPTLC2 interface thus emerging as a new therapeutic opportunity for retinal neurodegenerative diseases.